Company Overview

BeOne Medicines AG is a global oncology company dedicated to discovering, developing, and delivering innovative treatments for cancer patients worldwide. The company operates across the United States, China, Europe, and other international markets. Formerly known as BeiGene, Ltd., it officially changed its name to BeOne Medicines Ltd. in May 2025. Founded in 2010 and headquartered in Cambridge, Massachusetts, BeOne has expanded its operations to over 45 countries across six continents. The company underwent a rebranding to BeOne in late 2024 and redomiciled to Basel, Switzerland, in 2025.

Market Position and Financial Performance

As of August 2025, BeOne Medicines stock is trading at $297.96 per share, valuing the company at a market capitalization of $32.82 Billion. For the trailing twelve months ending June 30, 2025, BeOne Medicines reported revenue of $4.56 Billion.

Q2 2025 Financial Highlights

The second quarter of 2025 marked a significant milestone for BeOne, with total revenues increasing by 42% to reach $1.3 Billion. Key financial metrics from this quarter include:

- Global BRUKINSA Revenues: A 49% increase to $950 million.

- TEVIMBRA Sales: Showed a 22% growth.

- Gross Margin: A strong 87.4%.

- Free Cash Flow: Reported at $220 million.

- Full Year 2024 Revenue: $3.81 Billion, representing a substantial 54.96% increase from the previous year's $2.46 Billion.

Core Product Portfolio

BeOne Medicines focuses on developing groundbreaking therapies for hematologic malignancies and solid tumors.

BRUKINSA (Zanubrutinib)

BRUKINSA is an orally available, small-molecule inhibitor of Bruton's tyrosine kinase (BTK). It has surpassed $1.3 Billion in annual sales and is approved in major markets including the U.S., Europe, and China. BRUKINSA is considered the backbone of the company's hematology franchise and is recognized as the best-in-class BTK inhibitor, holding the most approved indications and leading the market in the U.S.

TEVIMBRA (Tislelizumab)

TEVIMBRA is a PD-1 monoclonal antibody approved for multiple cancer indications globally. The European Commission recently approved TEVIMBRA for the treatment of non-small cell lung cancer, following its demonstration of significant survival benefits in a Phase 3 trial.

Additional Products

The company's portfolio also includes Pamiparib, a selective small molecule PARP inhibitor, alongside its key products BRUKINSA and TEVIMBRA.

Comprehensive Pipeline Development

BeOne Medicines is actively engaged in developing a diverse pipeline of novel therapeutics spanning hematology and solid tumors. The company's extensive clinical-stage portfolio includes:

- Sonrotoclax (BGB-11417): A small molecule Bcl-2 inhibitor.

- BGB-16673: A BTK-targeting chimeric degradation activation compound effective against wild-type and mutant BTK.

- Ociperlimab (BGB-A1217): A TIGIT inhibitor.

- Zanidatamab: A bispecific HER2-targeted antibody.

In addition to its clinical development efforts, BeOne also maintains robust preclinical programs.

Strategic Partnerships and Global Operations

BeOne Medicines has established strategic agreements with leading industry players including Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novar. With a growing global team of over 11,000 colleagues across six continents, the company is committed to radically improving access to medicines for a significantly larger patient population worldwide.

Recent Developments and Future Outlook

Recent Clinical Milestones

BeOne Medicines recently announced positive topline results for Sonrotoclax in patients with relapsed or refractory Mantle Cell Lymphoma (MCL), underscoring continued progress within the company's hematology portfolio.

Financial Guidance

BeOne Medicines remains optimistic about its growth trajectory. The company has updated its full-year 2025 revenue guidance to be between $5.0 Billion and $5.3 Billion, primarily driven by BRUKINSA's market leadership and ongoing global expansion. BeOne anticipates achieving over 20 significant milestones in the next 18 months, focusing on expanding its hematology and solid tumor pipeline, with substantial advancements expected in clinical trials and regulatory approvals.

Investment Thesis

BeOne Medicines AG demonstrates robust performance, evidenced by an impressive year-to-date stock return of 65.69%. The stock has seen remarkable growth, with a 62.57% increase over the past 12 months. The company, currently valued at $33.67 Billion, has earned a "GREAT" financial health score according to InvestingPro analysis.

BeOne's strategic concentration on oncology, coupled with its proven ability to bring innovative treatments to market, positions it as a significant and influential player in the global pharmaceutical landscape. The company is driven by a core purpose: to transform cancer care and transcend borders, ensuring access to life-changing medicines for more patients around the world.